0001493152-22-030215.txt : 20221102 0001493152-22-030215.hdr.sgml : 20221102 20221102163052 ACCESSION NUMBER: 0001493152-22-030215 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221102 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221102 DATE AS OF CHANGE: 20221102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ELITE PHARMACEUTICALS INC /NV/ CENTRAL INDEX KEY: 0001053369 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223542636 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15697 FILM NUMBER: 221354603 BUSINESS ADDRESS: STREET 1: 165 LUDLOW AVENUE CITY: NORTHVALE STATE: NJ ZIP: 07647 BUSINESS PHONE: 2017502646 MAIL ADDRESS: STREET 1: 165 LUDLOW AVENUE CITY: NORTHVALE STATE: NJ ZIP: 07647 FORMER COMPANY: FORMER CONFORMED NAME: ELITE PHARMACEUTICALS INC /DE/ DATE OF NAME CHANGE: 19980121 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

November 2, 2022

Date of Report (Date of earliest event reported)

ELITE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada

001-15697

22-3542636

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

165 Ludlow Avenue, Northvale, New Jersey 07647

(Address of principal executive offices)

(201) 750-2646

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ELTP		OTCQB

Item 7.01 Regulation FD Disclosure.

On November 2, 2022, in a press release, Elite Pharmaceuticals, Inc., or Elite, reported positive results from pivotal fed and fasted bioequivalence studies for an undisclosed extended-release generic drug product in a class of medications called dopamine agonists. The results indicate that the generic product is bioequivalent to the branded product

The studies were single-dose crossover comparative bioavailability studies in healthy male and female volunteers in both the fed and fasting states. The results indicate that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 and contained in the press release furnished as Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is not incorporated by reference into any of Elite’s filings under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

Caution Concerning Forward-Looking Statements

This Current Report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Including those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this current report, readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, Elite’s ability to obtain FDA approval of the ANDA or the timing of such approval process, delays, uncertainties, inability to obtain necessary ingredients and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements are not guarantees of future action or performance, the timing or results of pending and future clinical trials, regulatory reviews and approvals by the Food and Drug Administration and other regulatory authorities, intellectual property protections and defenses, are discussed in Elite’s filings with the Securities and Exchange Commission, including its reports on Forms 10-K, 10-Q and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated November 2, 2022
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 2, 2022	ELITE PHARMACEUTICALS, INC.

	By:	/s/ Nasrat Hakim
		Nasrat Hakim, President and CEO

EX-99.1 2 ex99-1.htm

Exhibit 99.1

Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study

NORTHVALE, N.J. – November 2, 2022 – Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, today reported positive results from pivotal fed and fasted bioequivalence studies for an undisclosed extended-release generic drug product in a class of medications called dopamine agonists. IQVIA reported annual revenue for the twelve months ending August 2022 of $12 million for the generic market for this product.

The studies were single-dose crossover comparative bioavailability studies in healthy male and female volunteers in both the fed and fasting states. The results indicate that the generic product is bioequivalent to the branded product. Elite is compiling the data for this product to file an Abbreviated New Drug Application with the US Food and Drug Administration.

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products which have been licensed to Lannett Company, Prasco, LLC, Epic Pharma, LLC, and TAGI Pharma. Elite operates a cGMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties, and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite’s filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Elite Pharmaceuticals, Inc.

Dianne Will, Investor Relations

518-398-6222

Dianne@elitepharma.com

GRAPHIC 3 ex99-1_logo.jpg begin 644 ex99-1_logo.jpg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end EX-101.SCH 4 eltp-20221102.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 eltp-20221102_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 eltp-20221102_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Nov. 02, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Nov. 02, 2022
Entity File Number	001-15697
Entity Registrant Name	ELITE PHARMACEUTICALS, INC.
Entity Central Index Key	0001053369
Entity Tax Identification Number	22-3542636
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	165 Ludlow Avenue
Entity Address, City or Town	Northvale
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07647
City Area Code	(201)
Local Phone Number	750-2646
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	ELTP
Entity Emerging Growth Company	false

XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001053369 2022-11-02 2022-11-02 iso4217:USD shares iso4217:USD shares 0001053369 false 8-K 2022-11-02 ELITE PHARMACEUTICALS, INC. NV 001-15697 22-3542636 165 Ludlow Avenue Northvale NJ 07647 (201) 750-2646 false false false false false Common Stock, par value $0.001 per share ELTP EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 21 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://elitepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm eltp-20221102.xsd eltp-20221102_lab.xml eltp-20221102_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "eltp-20221102_lab.xml" ] }, "presentationLink": { "local": [ "eltp-20221102_pre.xml" ] }, "schema": { "local": [ "eltp-20221102.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 21, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ELTP", "nsuri": "http://elitepharma.com/20221102", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-11-02to2022-11-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://elitepharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-11-02to2022-11-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://elitepharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001493152-22-030215-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-030215-xbrl.zip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